Overview
- Aristotle Growth Equity Fund (Class I-2) returned 0.95% in Q4 2025, trailing the Russell 1000 Growth Index’s 1.12%.
- The fund credited Guardant Health’s contribution to Q4 performance to better-than-expected Q3 earnings, test volume growth, and news of acquiring a competitor.
- Guardant Health reported about $281 million in Q4 2025 revenue, a 39% year-over-year increase.
- Guardant Health closed at $95.27 on February 25, 2026, with a one-month return of -13.77% and a 12-month gain of 126.24%, valuing the company at $12.37 billion.
- Reported hedge fund ownership of Guardant rose to 50 portfolios at the end of Q3 2025 from 46 in the prior quarter, reflecting rising institutional interest alongside improving industry sentiment.